| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERA.09.20 |
| P698 | PubMed publication ID | 19445574 |
| P2093 | author name string | Michael B Atkins | |
| Ryan J Sullivan | |||
| P2860 | cites work | microRNAs exhibit high frequency genomic alterations in human cancer | Q24546369 |
| CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations | Q24618486 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Major response to imatinib mesylate in KIT-mutated melanoma. | Q27851428 | ||
| Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 | ||
| Vindesine as a single agent in the treatment of advanced malignant melanoma | Q28327120 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 | ||
| Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control | Q30485941 | ||
| Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients. | Q33337168 | ||
| A phase II study of bortezomib in the treatment of metastatic malignant melanoma | Q33366244 | ||
| CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium | Q33367168 | ||
| Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer | Q33369361 | ||
| Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group | Q33372613 | ||
| Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma | Q33379895 | ||
| A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel | Q46448115 | ||
| Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study | Q46463625 | ||
| Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis | Q46538518 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group | Q46619788 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). | Q48417717 | ||
| A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma | Q51751812 | ||
| Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. | Q54795672 | ||
| Phase I/II trial of tremelimumab in patients with metastatic melanoma | Q56900159 | ||
| Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. | Q33382481 | ||
| Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma | Q33476213 | ||
| Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine | Q33887196 | ||
| PDGFRA activating mutations in gastrointestinal stromal tumors. | Q34169772 | ||
| Blocking oncogenic Ras signaling for cancer therapy | Q34311585 | ||
| Somatic activation of KIT in distinct subtypes of melanoma | Q34569987 | ||
| Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c | Q34600089 | ||
| Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr | Q34747181 | ||
| Elesclomol induces cancer cell apoptosis through oxidative stress | Q34812609 | ||
| Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients | Q34959906 | ||
| Phosphoinositide 3-kinase in disease: timing, location, and scaffolding | Q36076050 | ||
| Raf: a strategic target for therapeutic development against cancer | Q36260492 | ||
| Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis | Q36612290 | ||
| Lack of clinical efficacy of imatinib in metastatic melanoma | Q36616712 | ||
| Desmoids in familial adenomatous polyposis are monoclonal proliferations | Q36641413 | ||
| Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic | Q36945203 | ||
| Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. | Q37093133 | ||
| A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study | Q38517711 | ||
| BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. | Q39920726 | ||
| The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways | Q39992436 | ||
| Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. | Q40014237 | ||
| Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice | Q40131849 | ||
| CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. | Q40155722 | ||
| Characterization of microRNA expression levels and their biological correlates in human cancer cell lines | Q40158414 | ||
| Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells | Q40396792 | ||
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 | ||
| Phase II study of thalidomide in patients with metastatic malignant melanoma. | Q40463781 | ||
| Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma | Q40534845 | ||
| Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | Q40578614 | ||
| Chemosensitisation of malignant melanoma by BCL2 antisense therapy | Q40611574 | ||
| Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells | Q40833834 | ||
| Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma | Q40912648 | ||
| A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors | Q40997984 | ||
| Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas | Q42810281 | ||
| Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines | Q42818580 | ||
| Isolation of a tumor factor responsible for angiogenesis | Q42835506 | ||
| Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial | Q44012091 | ||
| Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | Q44567819 | ||
| Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array | Q44594958 | ||
| Phase II study of thalidomide in patients with metastatic melanoma | Q44848608 | ||
| Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. | Q45197745 | ||
| Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. | Q46106546 | ||
| KIT gene mutations and copy number in melanoma subtypes | Q46267082 | ||
| Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study | Q46367364 | ||
| Effectively targeting BRAF in melanoma: a formidable challenge | Q46424236 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 567-581 | |
| P577 | publication date | 2009-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Review of Anticancer Therapy | Q2999044 |
| P1476 | title | Molecular-targeted therapy in malignant melanoma | |
| P478 | volume | 9 |
| Q36336131 | Effects of nuclear factor-κB and ERK signaling transduction pathway inhibitors on human melanoma cell proliferation in vitro |
| Q33863916 | Melanoma: a model for testing new agents in combination therapies |
| Q84774654 | Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination |
| Q39464868 | NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway |
| Q59333218 | Potential Epigenetic-Based Therapeutic Targets for Glioma |
| Q38043457 | ‘Malignant melanoma microecosystem’: Immunohistopathological insights into the stromal cell phenotype |
Search more.